CXCR4 as possible druggable target linking inflammatory bowel disease and Parkinson's disease

Dogra, Nitu; Mani, Ruchi Jakhmola; Potshangbam, Angamba Meetei; Buch, Shilpa; Katare, Deepshikha Pande

doi:10.1007/s11011-022-01155-6

Cited by 6 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MR Analysis of PD and IBD suggested that the CXCR4 gene is a potential drug target. The gene encodes the chemokine receptor CXCR4, and flavonoids may become potential therapeutic drugs for PD and IBD by inhibiting the CXCR4 protein (96). Therefore, new therapies for PD and IBD can be developed by finding the gene targets of drugs.…”

Section: Medicinementioning

confidence: 99%

Bidirectional communication of the gut-brain axis: new findings in Parkinson’s disease and inflammatory bowel disease

Wanyi,

Jiao,

Wen

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

Parkinson’s disease (PD) and inflammatory bowel disease (IBD) are the two chronic inflammatory diseases that are increasingly affecting millions of people worldwide, posing a major challenge to public health. PD and IBD show similarities in epidemiology, genetics, immune response, and gut microbiota. Here, we review the pathophysiology of these two diseases, including genetic factors, immune system imbalance, changes in gut microbial composition, and the effects of microbial metabolites (especially short-chain fatty acids). We elaborate on the gut–brain axis, focusing on role of gut microbiota in the pathogenesis of PD and IBD. In addition, we discuss several therapeutic strategies, including drug therapy, fecal microbiota transplantation, and probiotic supplementation, and their potential benefits in regulating intestinal microecology and relieving disease symptoms. Our analysis will provide a new understanding and scientific basis for the development of more effective therapeutic strategies for these diseases.

show abstract

Section: Medicinementioning

confidence: 99%

Bidirectional communication of the gut-brain axis: new findings in Parkinson’s disease and inflammatory bowel disease

Wanyi,

Jiao,

Wen

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…The results demonstrated that patients achieved durable SVR35 (≥35% spleen volume reduction) and improved TSS50 (≥50% reduction in total symptom score) (Harrison et al, 2022a). Moreover, potential natural products such as plant-derived cucurbitacin I and curcumin analogue ASC-J9 could be used as JAK/STAT inhibitors to treat related diseases (Yin et al, 2023), and the small molecule drugs, which screened from the databases (Dogra et al, 2023), targeting JAK/STAT could also be regarded as treatment strategies for related diseases (various organ fibrosis, etc.) (Liu et al, 2023).…”

Section: Combination Therapy With Jak/stat Inhibitorsmentioning

confidence: 99%

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Bian

Rong

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Janus kinase/signal transduction and transcription activation (JAK/STAT) pathways were originally thought to be intracellular signaling pathways that mediate cytokine signals in mammals. Existing studies show that the JAK/STAT pathway regulates the downstream signaling of numerous membrane proteins such as such as G-protein-associated receptors, integrins and so on. Mounting evidence shows that the JAK/STAT pathways play an important role in human disease pathology and pharmacological mechanism. The JAK/STAT pathways are related to aspects of all aspects of the immune system function, such as fighting infection, maintaining immune tolerance, strengthening barrier function, and cancer prevention, which are all important factors involved in immune response. In addition, the JAK/STAT pathways play an important role in extracellular mechanistic signaling and might be an important mediator of mechanistic signals that influence disease progression, immune environment. Therefore, it is important to understand the mechanism of the JAK/STAT pathways, which provides ideas for us to design more drugs targeting diseases based on the JAK/STAT pathway. In this review, we discuss the role of the JAK/STAT pathway in mechanistic signaling, disease progression, immune environment, and therapeutic targets.

show abstract

“…101 Common biological pathways linking both pathologies (i.e., IBD and PD) include HIF signaling, cytokine interactions, the JAK-STAT pathway, cholesterol metabolism, apoptosis, and CXCR4 signaling, which modulates synaptic function and survival in the mature brain. 103 Lifestyle, dietary, and environmental risk factors can modify both IBD and PD. High animal fat and polyunsaturated fatty acid intake have been correlated with an increased risk of both IBD 104 and PD.…”

Section: Association Between Ibd and Neurodegenerative Diseasesmentioning

confidence: 99%

Section: Association Between Ibd and Neurodegenerative Diseasesmentioning

confidence: 99%

The Interface between Inflammatory Bowel Disease, Neuroinflammation, and Neurological Disorders

et al. 2023

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a complex, chronic inflammatory condition affecting the gastrointestinal tract. IBD has been associated with a variety of neurologic manifestations including peripheral nerve involvement, increased risk of thrombotic, demyelinating and events. Furthermore, an evolving association between IBD and neurodegenerative disorders has been recognized, and early data suggests an increased risk of these disorders in patients diagnosed with IBD. The relationship between intestinal inflammatory disease and neuroinflammation is complex, but the bidirectional interaction between the brain-gut-microbiome axis is likely to play an important role in the pathogenesis of these disorders. Identification of common mechanisms and pathways will be key to developing potential therapies. In this review, we discuss the evolving interface between IBD and neurological conditions, with a focus on clinical, mechanistic, and potentially therapeutic implications.

show abstract

CXCR4 as possible druggable target linking inflammatory bowel disease and Parkinson's disease

Cited by 6 publications

References 46 publications

Bidirectional communication of the gut-brain axis: new findings in Parkinson’s disease and inflammatory bowel disease

Bidirectional communication of the gut-brain axis: new findings in Parkinson’s disease and inflammatory bowel disease

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

The Interface between Inflammatory Bowel Disease, Neuroinflammation, and Neurological Disorders

Contact Info

Product

Resources

About